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Abstract
The current research in oncology is focused on genetics and molecular oncology in order
to obtain better understanding of the etiology of tumor disease. Detailed knowledge of
oncogenesis mechanisms could lead to invention of effective therapeutic tools against
cancer.  Under  healthy conditions,  cell  cycle  is  regulated by oncogenes  and tumor
suppressor genes, which should be in strict balance. Genesis of tumor is a consequence
of the accumulation of genetic alterations, which help the cell to escape normal cellular
regulatory mechanisms and destruction by immune system. Glioblastoma (GBM) is a
highly malignant primary brain tumor occurring mostly in population of adults. Patients
suffering from GBM have very poor prognosis. Despite development in radiology methods
promising earlier diagnosis and development of clinical and radiation oncology with
newer treatment regimes, the effect of therapy remains limited and prognosis of patients
has not improved as expected. Target of GBM research are genes involved in response to
oxidative stress and DNA damage, genes regulating cell cycle, genes determining immune
response, growth factors, and others. Genetic alterations are studied in connection to their
possible relationship to susceptibility of brain tissue for tumor formation, to sensitivity
of brain tissue for various environmental etiology factors, to effect of anticancer treatment
or resistance of tumor tissue to therapy, to overall survival, and progression-free interval.
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1. Introduction
Glioblastoma (GBM) is a brain tumor of neuroectodermal origin. It is a second most common
primary brain neoplasm and the most common from malignant brain tumors. This tumor arises
from  neural  stem  cells  (NSCs),  progenitor  cells,  dedifferentiated  mature  neural  cells  or
neuroepithelial stem cells that transform into cancer stem cells (CSCs) or glioblastoma stem
(GSC) or stem-like cells [1]. Stem cells have a high potential of self-renewal and differentia‐
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tion. GBM is a tumor with highest degree of anaplasia within gliomas. It is classified as grade
IV according to the WHO classification of brain tumors from 2007. This lesion has a rapid growth,
is unbounded, infiltrates surrounding brain tissue, but rarely metastasizes. When metastases
occur, it is usually within the central nervous system. Typical histopathological features of this
tumor are cells of recognizably astrocyte origin, but displaying cellular pleomorphism with
multinucleation, frequent mitoses, and areas of necrosis surrounded by palisading nuclei
(increased tumor cell density) and endothelial proliferation as a manifestation of cellular
hyperplasia with numerous clusters of blood vessels forming so-called glomeruloid forma‐
tions. GBM cells spread along tracts in white matter infiltrate cerebrospinal fluid and vessels
between meningeal layers. Invasion of GBM cells begins with the degradation of surrounding
matrix proteins by proteases and proteinases. Movement of tumor cells through surrounding
brain tissue requires receptor turnover, formation and degradation of focal adhesion mole‐
cules and rearrangement of cytoskeleton components. These changes are consequences of genetic
alterations, such as overexpression, amplification, deletion or mutation in focal adhesion kinase
and phosphatidylinositol 3-kinase (PI3K) pathways [2] and mainly caused by activation of
growth factors and their receptors (integrins and protein deleted in colorectal cancer (DCC),
hyaluron receptors CD44, RHAMM, BEHAB, ontogenetic protein SPARC, receptors for platelet-
derived growth factor (PDGF), transforming growth factor (TGF)-α, epidermal growth factor
(EGF), and basic fibroblast growth factor (bFGF)). Some components of extracellular matrix
such as laminin or fibronectin are overexpressed in GBM and their silencing reduces invasive‐
ness of GBM cells [3]. Besides microscopic characteristics, GBM is connected with a huge amount
of genetic alterations causing higher proliferation, migration, and invasiveness of tumor cells.
The intrinsic ability of GBM cells to invade normal brain tissue impedes complete surgical
resection and predictably results  in early local  recurrence and mortality.  Thoroughgoing
explanation of GBM genetic pathways with their gene alterations is necessary for choosing of
more suitable therapy and in predicting patient prognosis. This chapter offers an overview of
the most common genetic alterations occurring in GBM.
2. Classification of GBM
According to the WHO classification of brain tumors based on histopathological origin, GBM
is a primary brain tumor of neuroepithelial, glial origin. Ranking of GBM in clinical and
prognostic significance is within the highest grade IV. GBM could also be classified according
to mode of occurrence, as it could be a result of progression from less malignant glial tumor
(so-called secondary type) or it could occur de novo (primary type). Another specific type is
pediatric GBM. The most common is primary type. Primary, secondary, and pediatric GBMs
have their own specific genetic and epigenetic alterations occurring in their gliomagenesis (see
Figure 1). As diagnosis of GBM presents with heterogeneity of altered genetic pathways
evidenced by The Cancer Genome Atlas Research Network’s study, classification based on
gene expression profile distinguishes a classical, mesenchymal, proneural, and neural type of
GBM. Classical type typically harbors no TP53 mutations, but very high rate of epidermal
growth factor receptor (EGFR) mutations. This type has a slightly better survival. Mesenchy‐
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mal type displays frequent mutations of neurofibromatosis gene 1 (NF1), TP53, and PTEN
genes and aggressive anticancer therapy brings a significant increase in survival of these
patients. Third, proneural subtype presents with highest mutation rate of TP53, PDGFRA, and
isocitrate dehydrogenase (IDH) and usually affects younger adults. Last, neural type occurs
more often in older population and contains several gene mutations at an average rate [4].
These classifications show high heterogeneity of genetic profile, aggressiveness, clinical
characteristics, and expected prognosis of GBM patients with a strong need of definite uniform
classification of subtypes leading to more specific treatment for each GBM subtype.
Figure 1. Genes involved in genesis of primary, secondary, and pediatric glioblastoma. *Gain of function through am‐
plification or mutation; ฀homozygous deletion or mutation.
3. Most frequent genetic alterations of GBM
As mentioned above, alterations of oncogenes and tumor suppressor genes could deflect cell
from normal cell cycle. Accumulation of genetic alterations of these genes initiates oncogenesis.
In oncogenes, lesion of one allele is sufficient to cause mutation. Activation of oncogene causes
avoidance of apoptosis and cell further proliferates. Amplification and activating mutation are
the most common genetic alteration of oncogenes. On the other hand, lesion of both alleles is
required to evoke mutation in tumor suppressor genes. These genes and their protein products
when activated inhibit cell proliferation. Frequently observed alterations are deletion and
inhibitory mutation.
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During years of genetic research, there have been established three critical genetic pathways
whose alterations lead to the formation of GBM: inactivation of p53 and retinoblastoma (RB)
pathways (see Figure 2), activation of the PI3K pathway, and deregulation of growth factor
(receptor tyrosine kinase—RTK) signaling (see Figure 3). TP53 signaling pathway is altered in
87% of GBMs, mostly affecting p53, murine double minute-2 (MDM2), MDM4, and cyclin-
dependent kinase (CDK)N2A genes. Approximately 78% of GBMs harbor RB signaling
disruption with most frequently altered genes: RB1, CDK4, CDK6, CCND2, and cyclin-
dependent kinase inhibitor 2 (CDKN2) family. Finally, RTK/RAS/PI3K activation was found
in 88% of tumors, affecting usually NF1, PIK3R1, and PIK3CA genes.
Figure 2. p53 and RB cell cycle and cell death signaling pathway. Proteins marked with full color are most frequently
altered in glioblastoma.
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Figure 3. RTK/RAS/PI3K pathway. Proteins marked with full color are most frequently altered in glioblastoma.
GBM is classified as primary or secondary according to altered genes. Primary GBM is a tumor
with de novo formation. On the other hand, GBM as a result of malignant transformation of
lower-grade glial tumor is called secondary [1]. Also, clinical manifestation and age of
diagnosis vary within these two types. Typical for primary GBM is very short anamnesis and
age over 50. On the contrary, patients with secondary GBM usually have previous anamnesis
of lower grade glioma and younger age depending on the age at the time of diagnosis of
preexisting lower grade glioma. Both – primary and secondary GBM – have their own specific
gene alterations occurring in their gliomagenesis (see Figure 1). Typical alterations for primary
GBM are homozygous deletion or mutation of EGFR, PDGFRα, MDM2, CDK4, and PI3K genes,
and amplification or mutation of CDKN2A/B, PTEN, NF1, and RB genes. Secondary GBM also
has some typical alterations, which are mutation of IDH and TP53 genes and 9p deletion. The
best-known prognostic factor of GBM, hypermethylation of methylguanin-O-methyltransfer‐
ase (MGMT) gene promoter, occurs in both primary and secondary GBM.
Gene TP53 is a crucial tumor suppressor gene located on 17p13.1. It is one of the most
frequently mutated genes in human tumor cells [5]. Protein p53 restricts cell proliferation and
growth, modulates cell reaction to DNA damage, activates DNA repair, causes cell arrest in
G1/S regulation point, and induces apoptosis, senescence, and autophagy. TP53 also regulates
neovascularization and cell differentiation [6]. Suppression of pluripotency and inhibition of
self-renewal of stem cells belong to the most recently discovered functions of TP53 [7]. TP53-
mediated apoptosis is almost not present in glioma cells. Dysfunction of TP53 disrupts the
p14ARF pathway, what delays apoptosis and that further promotes genome instability. [8].
High incidence of alterations is in p53-binding domain, mainly codons 175, 248, and 273.
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Polymorphism Arg72Pro is under suspicion of higher susceptibility to GBM, but this relation‐
ship is not yet definitely confirmed. Mutation or deletion of TP53 is found in 35% of GBM cases,
but is more frequent in astrocytomas grade II [6, 9] and plays a role in their progression to
secondary GBM. On the other hand, it is present in only about 10% of primary GBM [10].
Oncogene MDM2 is located on 12q14.3-q15. Protein product of this oncogene is E3 ubiquitin
ligase which acts like transcriptional factor. This ligase has five forms and two of them have
the ability to interact with p53. The function of this protein is suppression of cell cycle arrest
and apoptosis by negative effect on p53 and promotion of cell growth and renewal [11]. The
effect of MDM2 is repression of transcriptional activity of p53 and amplification or overex‐
pression of this oncogene completely excludes p53 from having an effect on cell cycle. MDM2
overexpression plays an important role in genesis of glioma, but it seems that they are not
involved in glioma progression into higher grade [12]. This overexpression is present in about
10–14% of GBM and is always connected with the presence of wild type TP53. It is an alternative
mechanism to disrupt p53 pathway in tumor genesis [6]. This alteration is typical for primary
GBM [12].
MDM4 is located on 1q32. MDM4 encodes mdm2-related protein, which has p53-binding
domain and RING finger domain. MDM4 binds p53 protein and so inhibits p53-mediated
transcriptional transactivation. It also binds MDM2 protein via RING finger domain. Overex‐
pression and amplification of MDM4 occur in GBM, though it is not common (7%). MDM4
alterations do not occur together with p53 or MDM2 alteration. It is an alternative mechanism
by which a small part of GBMs escapes p53-regulated growth control. This oncoprotein may
inhibit oncogenesis. Ubiquitin-specific protease 2a (USP2A) binds to MDM4, stabilizes it and
protects against degradation. USP2–MDM4 interaction could be a determinant of malignant
potential. MDM4 and USP2a are highly expressed in GBMs from patients with longer survival
[13].
RB gene located on 13q14.2 has a protein product RB, which controls cell cycle, and acts as a
gatekeeper to S-phase entry. RB protein is an end point of kinase activities of CDK4/6-cyclin
D complexes. Transcription factor E2F binds to RB protein, which is normally not phosphory‐
lated. Complex RB–E2F is a silencing complex restricting access to transcription factors.
Phosphorylation of RB leads to release of E2F and such conformation allows CDK2 to access
cell cycle during S-phase and this promotes another phosphorylation and that further inhibits
the binding of E2F to RB protein [14]. Mutation of this gene has the same effect on cell cycle as
the amplification of CDK4/CDK6 or mutation of CDKN2A/CDKN2B, but these alterations are
never present together. This means that gliomagenesis proceeds by only one of these alterna‐
tive genetic pathways. RB pathway is frequently altered in GBM and has a huge role in
gliomagenesis [15]. Alterations of RB pathway are present almost universally in human
cancers. It is very common in primary GBM, and is present in about 80% [4, 16]. Impaired RB1
expression is associated with increased tumor proliferation and decreased survival; however,
more direct correlation with prognosis is in astrocytomas grade II and III than in GBM [17].
Mutation or deletion of RB1 is present in 11% of GBM [16].
CDKN1A gene encodes protein p21 and is located on chromosome 6p. Protein p21 is a member
of kinase inhibitor protein family (KIP). Level of p53 protein regulates transcription of p21.
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Apoptosis and cell cycle arrest mediated by p53 induce transcription of p21. This protein
controls cell proliferation by regulatory binding to complexes of CDK. It negatively effects
complexes of cyclin E/CDK2 and cyclin A/CDK2 and activates cyclin D/CDK. CDKN1A
amplification is frequent in GBM [18].
Gene CDKN1B is localized on 12p13.1-p12. Its protein product is p27, which is also a member
of KIP family. This protein also binds to CDK complexes, inhibits cyclin E/CDK2 and cyclin
A/CDK2, and it activates cyclin D/CDK. In proliferating cells, p27 was found in complex with
cyclin D/CDK and in G1 – arrested cells, p27 was bound to cyclin E/CDK2. Very low levels of
expression [19] are typical of GBM.
On 9p21 are located genes CDKN2A (protein product p16) and CDKN2B (product p15). These
proteins are inhibitors of CDK and they inhibit phosphorylation of RB1 protein by binding to
cyclin D, what prevents their interaction with CDK4/6. Regulation of p16/p14ARF pathway is
determining the susceptibility to the only proved environmental risk factor of gliomagenesis
– ionizing radiation [20]. Higher risk of glioma formation was observed in patients with
CDKN2A and CDKN2B mutations [21, 22]. Homozygous deletion of CDKN2A is present in
almost 50% of gliomas and is connected with poor prognosis [14]. But polymorphisms of
CDKN2A/CDKN2B genes are not proved to be connected with tumor grade and prognosis [23].
Protein p14ARF is an alternate reading frame product of CDKN2A locus on 9p21. This protein
has tumor suppressor activity, regulates cell cycle, initiates p53-dependent cell cycle arrest and
apoptosis [20] and is induced by mitogenic stimulation. It inhibits MDM2 and so promotes
p53. The finding of p14ARF loss in conjunction with p53 gene loss suggests that the protein
may have other p53-independent tumor suppressor functions. P14ARF mediates antiangio‐
genic effects by upregulating expressions of tissue inhibitor of metalloproteinase-3 in p53-
independent fashion. About 60–80% of high-grade gliomas show loss of tumor suppressor
p14ARF activity by homozygous mutation [24].
CDKN2C gene has locus on 1p32, encodes protein p18, interacts with CDK4 and CDK6 and
prevents their activation. It functions as a cell growth regulator that controls G1 cell cycle
progression and also suppresses tumorigenesis. Homozygous deletion is a most common
cause of CDKN2C inactivation. This deletion occurs in tumors harboring also CDKN2A
deletions. Expression of CDKN2C is almost absent in 43% of GBMs. It is suggested that p16
deletion occurs as an early event in tumorigenesis and p18 inactivation should happen later
in tumor formation [25].
Genes CDK4 (12q14) and CDK6 (7q21-22) have protein products CDK4 and CDK6 with
catalytic kinase activity. Their inhibitors are proteins p15 and p16. CDK4 and CDK6 proteins
make complexes with cyclin D. Gene CDK6 is an oncogene, which is required for proliferation
of tumor cells and its viability [16]. Overexpression of CDK proteins inhibits the function of
their inhibitors – proteins p15 and p16. Amplification of CDK4 is observed in 18% and CDK6
in 1% of GBMs [16].
CCND2 gene (cyclin D2), locus 12p13, encodes a protein of cyclin family that function as
regulators of CDK kinases. Cyclin D2 makes a complex with CDK4 and CDK6 and works as
a regulatory subunit of this complex, which is required for G1/S cell cycle transition. Associ‐
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ation of cyclin D2 and CDK4/6 leads to phosphorylation of RB and RB-related proteins that
allows cell to enter S phase of cell cycle. Deregulation of this cell cycle transition often causes
formation of tumor and is frequently seen in GBM. Amplification of CCND2 occurs in 2% of
GBM cases. Study on in vitro GSC showed high expression levels of cyclin D2 and suppression
of its expression led in experimental model to G1 arrest. This suggests an important role of
cyclin D2 in cell cycle progression and in tumorigenicity of GSC [26].
PIK3CA gene (phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha)
located on 3q26.3 encodes ATP-dependent IA PI3K alpha catalytic subunit of phosphatidyli‐
nositol 3-kinase. This gene is a part of PI3K pathway, which plays a role in proliferation, cellular
metabolism, apoptosis, differentiation, migration, and survival [27]. Binding of RTK to its
receptor activates regulatory units of PI3K pathway, this activates catalytic subunits, which
phosphorylates phosphatidylinositol 4, 5-bisphosphate (PIP2), converts it to phosphatidyli‐
nositol 3, 4, 5-triphosphate (PIP3). PIP3 activates downstream signaling cascades as the AKT
and mTOR pathways, which are involved in proliferation and cell survival [28]. Hyperacti‐
vation of these pathways contributes to tumor progression. Mutations of this gene constitu‐
tively activate the PI3K catalytic activity and drive the GBM formation and progression [29].
Treatment of GBM with PI3K-targeted agents is promising [28]. PIK3CB gene (phosphatidy‐
linositol-4, 5-bisphosphate 3-kinase catalytic subunit beta) located on 3q22.3 encodes IA PI3K
beta catalytic subunit of phosphatidylinositol 3-kinase. This gene was identified as a marker
predicting recurrence and prognosis of GBM [30].
PIK3R1 gene (phosphatidylinositol-3-kinase regulatory subunit 1) located on 5q13.1 is also
part of PI3K pathway. Mutations and amplifications of these genes also occur in GBM [29].
PIK3R1 mutations act through the catalytic subunit by binding to it and inhibiting its activity
[31]. Result of such PIK3R1 mutation is no inhibition of catalytic subunit and so constant
activity of whole pathway leading to invasion and migration of tumor cells. Experimental
knockdown of PIK3CA and PIK3R1 leads to decrease in proliferation, migration, and invasion
of GBM cell lines [32].
Gene phosphatase and tensin homology – PTEN located on 10q23.3 is a tumor suppressor
gene. PTEN protein, product of this gene, is a lipid phosphatase counteracting the effect of
PI3K signaling. PTEN regulates this pathway by converting PIP3 to PIP2. After exposure to
ionizing radiation, PTEN acts as a critical determinant of cell fate between the senescence and
apoptosis [33]. Germ line mutations of PTEN were described in some autosomal hereditary
diseases, such as Cowden disease, Bannayan-Zonana syndrome, etc. Monosomy of chromo‐
some 10 is frequently present in GBM and rarely in low-grade astrocytoma. Inactivation of this
tumor suppressor gene is present in both primary and secondary GBM [6]. PTEN gene is
mutated or lost in 60–70% of GBM and this condition is associated with poor prognosis [18].
Signal transducer and activator of transcription 3 – STAT3 gene (locus 17q21.31) encodes a
protein member of STAT family. In response to growth factors or cytokines, this protein
becomes phosphorylated and acts as a transcription factor. STAT3 regulates cell growth,
nervous system development, stem cell differentiation, apoptosis, and is commonly activated
in tumors. It also regulates growth and self-renewal of GBM stem cells. STAT3 has an anti-
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apoptotic role, is activated in high percentage of GBM, and is required for maintaining of
multipotency of tumor cells [34].
Oncogene AKT3 (v-akt murine thymoma viral oncogene homolog 3) located on 1q44 codes a
protein, member of serine/threonine protein kinase family (AKT). These AKT kinases are
regulators of processes such as cell proliferation, differentiation, apoptosis, tumorigenesis,
glycogen synthesis, and glucose uptake and their overexpression induces cell survival and
malignant transformation. Enhanced DNA repair can allow damaged or mutated cells to
survive, contributing to resistance and tumor recurrence [35]. Inhibition of AKT kinases
activity leads to apoptosis. AKTs have three isoforms AKT1, AKT2, AKT3, being one of the
major downstream effectors of PI3K. AKT pathway is activated in 70% of gliomas and is
usually associated with PTEN mutations [36]. AKT3 is also essential for normal brain devel‐
opment [37] and is stimulated by PDGF, insulin, and insulin-like growth factor (IGF)1. AKT1
protein does not seem to be overexpressed in GBM, level of AKT2 increases with the malig‐
nancy grade and AKT3 expression decreases. It seems that AKT3 protein is affected by the
negative feedback caused by AKT2 overexpression. Even though ATK3 is downregulated, it
exhibits high kinase activity and retained the functional capacity as an oncoprotein and so may
inhibit the growth of malignant cells. AKT3 is often amplified in GBM [35]. AKT2 and AKT3
isoform-specific knockdown inhibits cell growth and induces apoptosis [38] and thus is a
potential target for therapy of AKT pathway-altered GBM.
NF1 (locus 17q11.2) codes tumor suppressor protein neurofibromin 1, Ras GTPase-activating
protein, which was first found to be mutated in a genetic neurodevelopmental disease
neurofibromatosis. Neurofibromin negatively regulates Ras and m-TOR signaling in astro‐
cytes. Approximately 23% of GBM harbor inactivating mutation of NF1, typically mesenchy‐
mal subtype. NF1 inactivation could be due to genetic loss or mutation or to extensive
proteasomal degradation [39].
MYC oncogene (v-myc avian myelocytomatosis viral oncogene homolog) has locus on 8q24.21.
Its protein product is a nuclear phosphoprotein and transcriptional factor with various
functions in cell cycle progression, cellular transformation, and apoptosis. Oncogenic activa‐
tion is achieved by mutation, amplification, overexpression, and chromosomal translocation.
This gene is an important target for the cooperative actions of p53 and PTEN in the regulation
of normal and malignant cell differentiation, self-renewal, and tumorigenic potential. Over‐
expression of MYC is present in up to 70% of GBM [40] and surprisingly is highly correlated
with better overall survival, what could be a result of enhancement of the proapoptotic effect
of upregulated MYC [41]. Moreover, a direct relationship was found between MYC overex‐
pression and MGMT methylation, so that MYC overexpression can be considered a good
indicator of response to temozolomide treatment [42].
BMI1 – polycomb ring finger oncogene (10p11.23) is a transcriptional epigenetic repressor of
genes governing self-renewal, differentiation, and proliferation, which is directly regulated by
MYC. It plays a role in the development of the cerebellum and is required for self-renewal of
stem cells in the hematopoietic, epithelial, and nervous system [43]. Overexpression of BMI1
is frequently present in GBM and is concurrent with MYC activation and MYC directly induces
upregulation of BMI1 [41, 44].
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Isocitrate dehydrogenase system comprises two genes: IDH1 located on 2q33.3 and IDH2
located on 15q26.1. Their products are enzymes (IDH1, IDH2, and IDH3) involved in citric
acid cycle. The function of IDHs in this basic metabolic pathway is to catalyze oxidative
decarboxylation of isocitrate to α-ketoglutarate and reducing NADP+ to NADPH (NAD+ to
NADH in case of IDH3). Crucial effect on interaction of an enzyme with a substrate has arginine
132 (R132) in IDH1 and R172 in IDH2. Mutations of these important areas lead to significant
reduction of enzyme activity [45, 46]. Mutations of IDH genes are common in patients with
secondary GBM, but rare in primary and pediatric (11%) GBM [47, 48]. The fact that IDH
mutations are found in a wide spectrum of histologic tumor types indicates that they occur as
an early alteration in tumorigenesis [49]. Only 3–7% of primary GBM shows IDH mutations,
but is often found in astrocytoma grade II and III and secondary GBM [50]. Though IDH
mutations in primary GBM are rare, they create a prognostically favorable subgroup [21]. Also,
IDH2 mutation, which is much less frequent than IDH1 mutation, occurs in gliomas [51], but
only in about 6% of secondary GBMs [52]. There is also a possible association between the
presence of IDH1 mutation and longer overall survival in patients with GBM [53, 54]. Fur‐
thermore, IDH mutation appears to be a significant marker of positive chemosensitivity in
secondary GBM. Patients with this mutation show a higher response rate to temozolomide,
which is widely used in chemotherapy of malignant gliomas. This makes IDH mutation an
independent favorable prognostic factor for overall survival with comparable importance to
hypermethylation of MGMT promotor [52]. Patients having both IDH mutation and MGMT
promoter methylation seem to have best response to therapy and progression-free survival.
Mechanism leading to increased effect of chemotherapy is not clearly known, it is possible that
IDH mutation promotes treatment-induced apoptosis by inhibiting the cell-protective
mechanisms against oxidative stress [55]. Prolonged survival of secondary GBM patients with
IDH mutation was proved in patients with tumors of astrocytic, but not oligodendroglial origin
[56]. Tumors with IDH mutation often show also the presence of TP53 mutation; on the other
hand, tumors with wild type IDH often have alteration typical for primary GBM (PTEN, EGFR,
CDKN2A, or CDKN2B). This fact confirms the existence of separate genetic pathways for
primary and secondary GBM [50]. IDH mutations are novel and very important and useful
prognostic factor of gliomas [21]. An inhibitor of IDH1 significantly retards GBM growth
through inducing differentiation [57].
DCC gene with locus on 18q21.3 has product DCC protein. This protein is highly expressed
in the nervous system. DCC is a transmembrane protein and creates part of the receptor for
netrin 1. Netrins play a role in direct cell and axon migration during neural development. Their
expression is also detectable in adult tissue, but their function is not yet clear [58]. DCC induces
apoptosis and cell cycle arrest in G2 phase. Also plays a role in chemo-attraction to netrin-1
slowing the rate of spontaneous cell migration. DCC has probably anti-oncogenic function,
although if disruption of netrin signaling contributes to tumorigenesis is not yet understood
[59]. According to immunohistochemical examination, expression of DCC decreases in many
malignancies including GBM and also decreases during progression from low-grade astrocy‐
tomas to GBM. This points out the connection of DCC with the formation of secondary, but
not with primary GBM [59].
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Paternally expressed gene 3 – PEG3, located on 19.chromosome, is an imprinted gene ex‐
pressed mainly during embryogenesis, but also in some adult tissues – ovary, testis, muscle,
and brain [60]. Overexpression is frequent in oligodendrogliomas, for GBM very low expres‐
sion is typical. Deregulation of PEG3 induces the formation of gliomas [61].
GST genes – glutathione S-transferases genes: GSTP1 (location 11q13), GSTM1 (1p13.3), GSTT1
(22q11.23), and GSTO1 (10q25.1). Proteins of these genes are phase II biotransformation
enzymes, which detoxify a wide range of exogenous agents including carcinogens. GSTs are
responsible for glutathion conjugation of alkylators and scavenging of free radicals generated
by radiation [62]. These enzymes provide enzymatic and nonenzymatic functions. GSTs also
have important roles in cellular processes as cell proliferation, apoptosis, oncogenesis, tumor
progression, drug resistance, and cell response to stress [63]. Genetic variations of GST genes
determine the response to carcinogens. Polymorphisms of these genes result in absent or
altered enzyme activity and are associated with survival rate in cancer patients. The relation‐
ship between these polymorphisms and brain tumor risk is not clear, although there have been
some results referring to possible association between GSTM1 null genotype and brain tumor
incidence [64]. Patients with brain tumors and GST polymorphisms have higher risk of adverse
effects of chemotherapy with nitrosourea alkylating agents.
EGF gene is located on 4q25. EGF is a ligand for its receptor (EGFR), inducing a dimerization
of one or several members of the EGFR family (ErbB1-4). This activates several tyrosine kinases
and other downstream signal molecules promoting transcription in the cell nucleus [65]. These
molecules are important for cell proliferation, survival, migration, and differentiation. EGF
polymorphism 61G/A on the promoter part of this gene is associated with glioma susceptibility
and with the degree of malignancy [66]; however, results of studies are controversial, probably
due to diverse distribution of EGF gene frequencies among the different ethnic groups. EGF
61G/A polymorphism is also probably associated with the survival time of glioma patients [67].
EGFR gene, located on 7p12, encodes EGFR protein, which is a transmembrane receptor
responsible for communication with its extracellular ligands – EGF and TGF-α and for
transmission of their signalization within the cell. EGFR has an effect on cell apoptosis,
angiogenesis, tumor proliferation, and ability to metastasize and is connected to sensitivity to
therapy and drug resistance. EGFR is the most frequently amplified gene in astrocytomas,
mainly in GBM. Expression of EGFR is higher in high-grade and poorly differentiated GBMs.
Both overexpression and amplification of EGFR are correlated with tumor progression. Over
50% of GBM have mutations of EGFR. Presence of EGFR mutation is associated with early
relapses and poor prognosis [68]. These mutations exist in three variations: EGFRvIII, δEGFR,
and de2-7EGFR (deletion, loss of exons 2-7 of mRNA strand). δEGFR promotes tumorigenesis
of GBM by increasing cellular proliferation, decreasing apoptosis, and promoting tumor cell
invasiveness. Amplification and de2-7EGFR-specific mutation is typical for primary GBM, in
which monosomy of chromosome 10 is also simultaneously present. Amplification of EGFR
is mostly associated with CDKN2A deletion, but usually occurs without homozygote deletion
or mutation of PTEN. Alteration of EGFR alone is probably not sufficient to cause tumorigen‐
esis, but another alteration in RB1 pathway is required.
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PDGF exists in five types of dimers consisting of four types of polypeptides, each encoded by
a different gene – A, B, C, and D. PDGFA (7p22), PDGFB (22q13.1), PDGFC (4q32), and PDGFD
(8q11). This system comprises two receptors: PDGFR-α (gene PDGFRA, 4q11-q13) and
PDGFR-β (gene PDGFRB, 5q31-q32). PDGF system is involved in cell cycle regulation, cell
migration, and chemotaxis and has also developmental functions – also in glial development
[69]. PDGFR-α is expressed only in subset of GBMs. PDGFR-β is more commonly expressed
in GBM by self-renewing GBM stem cells. PDGF pathway aberrations are mostly associated
proneural and mesenchymal subtypes of GBM [70]. Overexpression of PDGF and its receptors
is often found also in low-grade gliomas, suggesting this alteration as an early oncogenic event
and if often found in secondary GBM [71].
IGF system is composed of two ligands: IGF1 (gene IGF1, 12q23.2), IGF2 (also called somato‐
medin A, gene IGF2, 11p15.5), their receptors: IGF1R (15q26.3) and IGF2R (6q26), six binding
proteins (IGFBP 1-6), and various IGFBP-related peptides. IGF has a role in regulation of cell
processes. IGF1 is a major physiological mediator of the growth hormone and has a huge
influence on cell proliferation and differentiation. It inhibits apoptosis by blocking the
initiation of the apoptotic pathway. IGF1R is involved in malignant transformation processes.
IGF-binding proteins modulate interactions between IGF and IGFR. IGFBP3 (located on 7p13-
p12) acts as an apoptotic agent and inhibits the activity of IGF1 and has growth-promoting
effects [72]. Amplification of IGF1, IGF2, and IGF1R genes occurs in gliomas and other cancers.
No association between IGF polymorphism and GBM risk has been found.
FGF system is a family of factors involved in various cellular processes, such as developmental,
mitogen, cytoprotective, and angiogenic functions. System comprises 18 ligands and four FGF
receptors and FGF-binding protein, which increases FGF2-dependent proliferation of fibro‐
blast cells and may have an important role in oncogenesis. FGF2 (bFGF, 4q27-q25), known as
a pro-angiogenic factor for vessel formation and wound repair, is a potential oncoprotein in
GBM. Upregulated FGF2–FGFR1 signaling is implicated in the pathogenesis of GBM. Over‐
expression of FGF2 promotes GBM cell proliferation and also exerts an anti-apoptotic function
by upregulating of anti-apoptotic genes BCL-2 and BCL-X and thus making tumor resistant
to chemotherapy [73]. FGF2 also modulates apoptosis and thus promotes survival via resist‐
ance to radiation-induced cell death [74].
Vascular endothelial growth factor – VEGF system is the most potent angiogenesis- and
vasculogenesis-promoting system. There are known six VEGF ligands and three receptors
(VEGFR1, locus 13q12, VEGFR2, locus 4q11-q12, VEGFR3, locus 5q34-q35). VEGF system
stimulates endothelial cell migration, growth, proliferation, and survival, also acts as micro‐
vascular permeability factor and increases extravasation of plasma proteins [75]. Activation of
endothelial nitric oxide (NO) synthase leads to generation of NO and thus further activates
angiogenesis. The main angiogenic effect of this system is mediated by interaction of VEGF
(VEGFA) with VEGFR2. Angiogenesis is crucial for tumor formation, growth, and mainte‐
nance of blood supply. As the tumor develops, it may activate secondary angiogenic pathways,
such as bFGF, TGF, and PDGF. GBMs exhibit high levels of VEGF [76]. Higher vascular
permeability leads also to radiologic postcontrast enhancement. GBMs with high levels of
VEGF are more likely to exhibit ring-like enhancement, what makes relatively clear border on
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postcontrast imaging. In such tumors, the gross total resection is easier to obtain. High
expression of VEGF is associated with poor prognosis, but there are other factors determining
prognosis, such as the extent of resection [76].
TGFβ superfamily is involved in morphogenesis, embryonic development, adult stem cell
differentiation, immune reaction, wound healing, and inflammation [77]. This superfamily
comprises over 30 proteins divided into two branches: TGFβ subfamily and the bone mor‐
phogenetic protein-like (BMP-like) group. The TGFβ subfamily contributes to carcinogenesis
and makes tumors more aggressive and BMP-like group has a tumor suppression effect [78].
TGFβ subfamily is composed of three isoforms coded by three different genes – TGFBI (19q13),
TGFBII (1q41), and TGFBIII (14q24). This subfamily regulates cell proliferation, differentiation,
and extracellular matrix production [79]. All three isoforms are widely expressed in GBM, but
TGFβ expression is increased in mesenchymal GBM [80].
Proto-oncogene MET (7q31) codes hepatocyte growth factor receptor with tyrosine kinase
activity and belongs to RTK family. This receptor is usually expressed in epithelial cells. MET
after binding with its ligand hepatocyte growth factor (HGF) plays a role in various cellular
signaling pathways involved in proliferation, motility, migration, invasion, and tissue
homeostasis by activating the RAS, PI3K, STAT, beta-catenin, and NOTCH signal transduction
pathways [81]. It is aberrantly activated in many cancers (lung, pancreas, ovary, salivary gland,
and breast cancers) as well as in GBM via mutation, amplification, or overexpression. Mutation
of MET in GBM is rare [4]. Amplification is present in 5% and overexpression in 13% of GBM
[82]. Overexpression and amplification of MET are not perfectly concordant. This abnormal
activation of MET promotes malignancy and is partially associated with the aggressiveness as
it was found only in grade IV, not in grade II or III gliomas, but relationship to prognosis is
not clear [82, 83]. Amplification of EGFR could be associated with aberrant MET expression [4].
Under research are MET inhibitors in GBM treatment. Moreover, targeting the MET pathway
potentiates the responsiveness of GBM to γ-radiation [82].
HGF gene (7q21.1) codes for HGF protein, a pleiotropic factor and cytokine, promoting cell
proliferation, survival, motility, scattering, differentiation, and morphogenesis [84]. It is
usually expressed by mesenchymal cells, but could be secreted also by tumor cells. In addition,
HGF has a protective function in several diseases, including liver cirrhosis and promotes tissue
regeneration. It also stimulates mobility and invasiveness of tumor cells and induces angio‐
genesis [81]. GBM with autocrine activation of HGF has also activated MET signaling and that
predicts sensitivity to MET inhibitors in treatment [85]. HGF serum levels serve as biomarkers
of responsiveness to such therapy. HGF levels in serum and cerebrospinal fluid correlate with
prognosis, and are associated with higher mortality and recurrence rates [86].
Gene ATRX (α-thalassemia/mental-retardation-syndrome-X-linked), located at Xq21.1, was
discovered as a gene responsible for rare developmental disorder characterized by α-thalas‐
semia and intellectual impairment. It also has a role in the regulation of transcription, hetero‐
chromatin structure, and genome stability and is frequently deregulated in human cancer [87].
ATRX alterations are commonly present together with IDH and TP53 mutations. They are
detected in 80% of secondary GBMs, but only in 7% of primary [88]. Mutations of ATRX gene
are frequent also in pediatric GBM [89].
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The B-Raf proto-oncogene serine/threonine kinase – BRAF gene, located on 7q34, is a member
of Raf kinase family and serves as a strong activator of the extracellular signal-regulated kinase/
mitogen-activated protein kinase 1 and 2 (Erk 1/2) signal transduction cascade which modu‐
lates cell growth, proliferation, migration, differentiation, and apoptosis. Mutations of BRAF
gene usually occur at codon 600, which is a site of activation loop of the kinase domain.
Consequence of this BRAF V600E mutation is a protein with increased kinase activity. This
mutation is usually present in lower-grade gliomas, but was found in 54% of epithelioid GBM
[90], in 7% of giant cell GBM [91]. Within classical GBM types, BRAF mutation was present in
8% of adult and in 12% of pediatric GBM cases. These GBMs were all classified as primary. In
adults, they create a group of tumors that are present in younger age (mean age of 39 years),
none of these tumors harbored IDH mutation and seem to have slightly longer survival [92].
GBMs with BRAF V600E mutation may represent a small, but more favorable subgroup. In
such patients, BRAF/MEK inhibitor treatment may be beneficial in combination with other
therapies [93].
H3 histone, family 3A – H3F3A gene, located on 1q42.12, encodes replication-independent
histone H3.3. Histones are basic nuclear proteins responsible for the nucleosome structure of
the chromosomal fiber. ATRX and DAXX genes are encoding subunits of a chromatin remod‐
eling complex required for H3.3 incorporation at pericentric heterochromatin and telomeres
[94]. The histone H3.3 mutations result in amino acid substitution at K27 or G34 – two critical
positions within the histone tail involved in key regulatory posttranslational modifications.
H3F3A mutations are often seen in tumors with somatic TP53 mutation, within histological
grades are specific for GBM and are highly prevalent in children and young adults, and they
are present in one-third of pediatric GBMs [95]. Interestingly, K27-mutated tumors were
predominantly seen in midline structures – thalamus, pons (diffuse intrinsic pontine gliomas),
and spinal cord and have potentially poor prognosis. G34-mutated GBMs have better overall
survival [96].
Telomerase reverse transcriptase –TERT gene is located on 5p15.33. This gene encodes the
enzymatic core of telomerase. Telomeres are repeated sequences of DNA at the ends of
chromosomes. Under physiological conditions, as the cell divides, telomeres become progres‐
sively shorter. Telomerase counteracts the shortening of telomeres by adding small segments
of DNA at the end of chromosome after each cell division. Enhanced telomerase activity
facilitates cellular immortality and promotes oncogenesis. Mutations of TERT promoter
unmask binding sites for transcription factors, upregulate TERT expression and cellular
telomerase activity [97]. TERT mutations are much more common in primary GBM and are
inversely correlated with IDH mutations. Primary GBMs with TERT mutation exhibit signif‐
icantly shorter overall survival than TERT-wild type tumors [98]. This unfavorable prognosis
was absent after gross total resection and temozolomide therapy, what may indicate that TERT
mutation makes tumor more susceptible to chemotherapy.
Tumor suppressor PARK2 gene (parkin RBR E3 ubiquitin protein ligase) has locus on 6q25.2-
q27. The exact function of this gene is still to be explored. It codes an E3 ubiquitin ligase
mediating the targeting of substrate proteins for proteasome degradation. Germ line mutations
of this gene cause Parkinson’s disease, somatic mutations contribute to cancer. PARK2 is one
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of the most commonly inactivated tumor suppressor genes in GBM [99]. Deletion or inacti‐
vating mutation of this gene causes inability of PARK2 to promote ubiquitination and results
in cyclin E deregulation, which can promote tumor cell growth. Low expression of PARK2 is
associated with poor survival [100].
MGMT gene encodes a protein with alkyltransferase activity. MGMT is a DNA repair enzyme,
which is responsible for tumor resistance to alkylating and methylating agents. Activity of this
enzyme is regulated by this promoter area. This promoter, when methylated, causes inacti‐
vation of MGMT. Approximately 44% of GBM has MGMT promoter methylation [21].
Methylation status of MGMT is clinically the most relevant molecular parameter to predict
sensitivity of gliomas do DNA alkylating chemotherapeutics [101]. This methylation is
associated with prolonged progression-free survival and overall survival in patients with GBM
treated with alkylating agents, such as temozolomide. [102]. Expression of MGMT is not
associated with tumor grade [68].
4. Conclusion
GBM is the most aggressive and devastating primary brain tumor with very grim prognosis.
The patient’s survival rarely exceeds a year and a half with all accessible therapy used. Only
3% of GBM patients have survival over 5 years. This fact makes this tumor a very severe
diagnosis directly affecting life expectancy of the patient and quality of his/her life. Explanation
of its genesis could bring us closer to invention of effective treatment and genetic profile of
concrete GBM tissue would help to design the individualized therapy management for each
patient. Understanding the genetic and epigenetic characterization could help to distinguish
various GBM subgroups, indistinguishable by histological appearance, but classified accord‐
ing to molecular and genetic alterations. This could lead to establishment of GBM classification
with clinical impact, subgroup-specific treatment, and better design of future trials. The aim
was to achieve prolonged progression-free interval and overall survival with maintaining
satisfactory quality of life. It is very important if concrete genetic alteration is connected to
tumor formation or if it is prognostic factor. Other factors influencing prognosis are histological
type and tumor grade, age of patient, Karnofsky performance score at the time of diagnosis,
extend of surgical resection, tumor localization, and appropriate therapeutic management.
Tumor localization and extend of its surgical resection influence progression-free interval as
well as overall survival. Detailed and complete explanation and discovery of altered genes and
whole genetic pathways of GBM is the basis for new distinctive GBM classification. Such a
new tumor division could bring us closer to routine genetic examination of frequently altered
genetic pathways from tumor sample and aiming of therapy directly against specific genetic
and epigenetic targets. Such individualized therapy could decrease the number of adverse
effects, but first of all, hopefully, would finally ameliorate survival and life quality of patients,
suffering from this severe disease.
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